Press Release

Glythera and IONTAS enter into license agreement for the development of multiple antibodies for next-generation Antibody Drug Conjugates

IONTAS will provide Glythera with antibodies from its fully human antibody libraries Glythera will use these antibodies, in combination with its novel toxin portfolio, to develop next generation ADCs with improved efficacy and safety, to target difficult-to-treat tumours Cambridge and Newcastle, UK, 20th September, 2017: Glythera Limited (‘Glythera’), the next generation Antibody Drug Conjugate (‘ADC’) development Company, and IONTAS Limited (IONTAS), a leader in services and platform technologies associated with the discovery and optimisation of fully human antibody drugs, today…

Read more>>

Glythera appoints Dr Mike Owen as non-executive director

Glythera Limited (‘Glythera’), the next generation antibody drug conjugate (‘ADC’) development company, is pleased to announce the appointment of Dr Mike Owen to the Board as a non-executive director with immediate effect. Mike brings over 15 years of experience in the development and commercialisation of biopharmaceuticals. He was previously Senior Vice President and global Head of Research of the Biopharmaceuticals R&D Unit  at GlaxoSmithKline and was responsible for initiating and rapidly growing GSK's robust pre-clinical and clinical therapeutic antibody pipeline…

Read more>>

Glythera launches UK government funded project to develop safer and more efficacious ADCs for the treatment of difficult-to-treat tumours

- Development of proprietary next generation ADC portfolio -  - Secures £1m in grant funding - Glythera Limited (‘Glythera’), the next generation antibody drug conjugate (‘ADC’) development company, today announces the launch of a £1 million Innovate UK grant-funded project to develop next-generation ADCs for difficult-to-treat tumours using Glythera’s proprietary non-maleimide conjugation platform, PermaLink®, in combination with its portfolio of novel toxins and antibodies. ADCs are an emerging class of targeted therapeutics in the fight against cancer. By combining the…

Read more>>